Head of the Epigenetics Laboratory; NHMRC Senior Principal Research Fellow; Fellow of the Australian Academy of Science
Susan Clark is a molecular biologist by training and completed her BSc (Hons1) degree under the supervision of Drs Ken Reed and Lyn Dalgarno at the Australian National University, ACT, Australia in 1978. She studied for PhD (1982) in Biochemistry at University of Adelaide, South Australia, mapping and sequencing human histone genes, under the supervision of Dr Julian Wells.
Susan spent her postdoctoral years at Biotechnology Australia from 1983-1988 leading studies on the first recombinant vaccine development in Australia and eukaryotic expression of human inhibin, Il-3 and GMCSF. In 1992, she returned to basic research as Group Leader of the Gene Regulation Unit at the Kanematsu Laboratories, Royal Prince Alfred Hospital where she developed and implemented bisulphite sequencing for DNA methylation analysis. In 2000, she established and headed the Epigenetics Group at the Sydney Cancer Centre, Royal Prince Alfred Hospital and in 2004 moved her group to the Garvan Institute of Medical Research and initiated and led the growth of the Epigenetics Research Program in the Cancer Research Division. In 2015 she was appointed the inaugural Head of the Genomics and Epigenetics Division.
Her DNA methylation studies over the last twenty five years have initiated profound questions about the importance of epigenetics in early development and in disease, especially in cancer. Susan has made extensive ground-breaking discoveries relating to DNA methylation patterns in normal and cancer genomes, that have led to the commercialization of new methylation-based tests for early cancer detection. The techniques she pioneered in the early 1990s, including bisulphite sequencing, have revolutionised and now underpin the new era in epigen"omic" research. She was founding member of IHEC (International Human Epigenome Consortium) and led the formation and is president of the AEpiA (Australian Epigenetics Alliance).
She has a number of awards including the RPAH Research Medal (2002); the Julian Wells Medal (2003), for “outstanding contribution to gene action and genome structure”; the Ruby Payne-Scott Award (2004) for contribution of women in science; The German United Association Award for pioneering work in development of bisulphite sequencing; Australia’s “Top Ten” (NHMRC) Scientist Project Grant Award (2009); Rotary Award for Vocational Excellence (2012); awarded a NHMRC Senior Principal Research Fellowship (2014) and she was elected a Fellow of the Australian Academy of Science (2015) and received a Cancer Institute NSW “Make a Difference award” and in 2017 was awarded The Clive and Vera Ramaciotti Foundation: Medal of Excellence.
Awards and Honours
2015 - Elected a Fellow of the Australian Academy of Science
2015 - The Rob Sutherland Make a Difference ($20K), CINSW
2015 - Nadine Watson Lecture Award for a Leading Female Scientist
2014 - Senior Principal Research Fellowship (NHMRC)
2012 - Rotary Award for Vocational Excellence
2011 - Victor Chang Medal (Barbara Ell Seminar Series Lecturer)
2010 - Service to Science and Industry, North Shore Times, 50 year medal
2009 - Australia’s “Top Ten” (NHMRC) Scientist Award for 2009
2009 - Promoted Senior Principal Research Fellow (Garvan Institute)
2008 - Principal Research Fellowship (NHMRC)
2008 - Adjunct Professor, Faculty Medicine, University of NSW
2008 - Director’s Inaugural Women in Science Lecture Award (WEHI)
2006 - World Technology Award, finalist for 2006 for Biotechnology: the most innovative people in the science and technology world in 2006
2006 - Elected a Fellow of the World Technology Network for Biotechnology for contribution to Epigenetics technology
2004 - Principal Research Fellowship (NHMRC)
2004 - The Ruby Payne-Scott Award for women in Australian science
2004 - German Science Prize “Biochemisch Analytik Preis” (50,000 Euros) for outstanding contribution for Methylation analysis. Since 1970, this award has recognized the work of 27 world-renowned scientists, four of whom have subsequently gone on to win a Nobel Prize
2003 - Julian Wells Medal for “outstanding contribution to gene action and genome structure”, Lorne Genome conference
2002 - RPAH Research Medal for $50,000 for major contribution to research
1998 - Cancer Council NSW Travelling Award
1997 - DNA Methylation Imprinting and the Epigenetics of Cancer, AACR, Research Presentation Award, Puerto Rico
1978 - Commonwealth Post Graduate Research Award
1976 - CRAC Undergraduate Exchange Travelling Award to study at Cambridge
1978 - BSc (Hons1) - Australian National University, ACT - Australia
1977 - BSc, Australian National University, ACT - Australia
Valdés-Mora F, Gould CM, Colino-Sanguino Y, Qu W, Song JZ, Taylor KM, Buske FA, Statham AL, Nair SS, Armstrong NJ, Kench JG, Lee KML, Horvath LG, Qiu M, Ilinykh A, Yeo-Teh NS, Gallego-Ortega D, Stirzaker C, Clark SJ (2017). Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer. Nature Communications 8:1346. doi: 10.1038/s41467-017-01393-8.
Clark SJ, Molloy PL (2017). Smoke-Induced Changes to the Epigenome Provide Fertile Ground for Oncogenic Mutation. Cancer Cell 32:278-280. doi: 10.1016/j.ccell.2017.08.016 (Commentary).
AchingerKawecka J, Taberlay PC, Clark SJ (2017). Alterations in ThreeDimensional Organization of the Cancer Genome and Epigenome. Cold Spring Harb Symp Quant Biol 81:4151. doi: 10.1101/sqb.2016.81.031013
Skvortsova K, Zotenko E, Luu PL, Gould CM, Nair SS, Clark SJ*, Stirzaker C* (2017). Comprehensive evaluation of genome-wide hydroxymethylcytosine profiling approaches in human DNA. Epigenetics & Chromatin 10:16. doi: 10.1186/s13072-017-0123-7. * Equal Last Authors
Stirzaker C, Song J, Ng W, Du Q, Armstrong N, Locke W, Statham A, French H, Pidsley R, Valdes-Mora F, Zotenko E, Clark SJ (2017). Methyl-CpG-Binding Protein MBD2 plays a key role in maintenance and spread of DNA methylation of CpG islands and shores in cancer. Oncogene 36:1328-1338. doi: 10.1038/onc.2016.297.
Pidsley R, Zotenko E, Peters T, Lawrence MG, Risbridger GP, Molloy P, Van Dijk S, Muhlhausler B, Stirzaker C*, Clark SJ* (2016). Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biology 17:208. * Equal Last Authors
Taberlay PC, Achinger-Kawecka A, Lun ATL, Buske FA, Sabir K, Gould CM, Zotenko E, Bert SA, Giles KA, Bauer DC, Smyth GK, Stirzaker C, O’Donoghue SI, Clark SJ (2016). Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations. Genome Research, 26:719-31.
BLUEPRINT consortium (Qu W, Nair S, Statham A, Stirzaker C, Clark SJ (2016). Quantitative comparison of DNA methylation assays for biomarker development and clinical applications. Nat Biotechnology, 34:726-37.
Colino-Sanguino Y, Clark SJ*, Valdes-Mora F* (2016). H2A.Z acetylation and transcription: ready, steady, go! Epigenomics, 8:583-6 *Equal Last Authors (Review).
Stirzaker C, Zotenko E, Song JZ, Qu W, Nair SS, Locke WJ, Stone A, Armstong NJ, Robinson MD, Dobrovic A, Avery-Kiejda KA, Peters KM, French JD, Stein S, Korbie DJ, Trau M, Forbes JF, Scott RJ, Brown MA, Francis GD and Clark SJ (2015). Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nat Communications 6:5899.
Stone A, Zotenko E, Locke WJ, Korbie D, Millar EK, Pidsley R, Stirzaker C, Graham P, Trau M, Musgrove EA, Nicholson RI, Gee JM and Clark SJ (2015). DNA
methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. Nat Communications 6:7758.
Du Q, Luu PL, Stirzaker C and Clark SJ (2015). Methyl-CpG-binding domain proteins: readers of the epigenome. Epigenomics 1-23 (Review).
Locke WJ, Zotenko E, Stirzaker C, Robinson MD, Hinshelwood RA, Stone A, Reddel RR, Huschtscha LI and Clark SJ (2015). Coordinated epigenetic remodelling of transcriptional networks occurs during early breast carcinogenesis. Clinical Epigenetics 7(1):52.
Mahon KL, Qu W, Devaney J, Paul C, Castillo L, Wykes RJ, Chatfield MD, Boyer MJ, Stockler MR, Marx G, Gurney H, Mallesara G, Molloy PL, Horvath LG and Clark SJ; PRIMe consortium (2014). Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer 111:1802-9
Taberlay P, Statham A, Kelly TK, Clark SJ* and Jones PA* (2014). Reconfiguration of nucleosome depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res: doi:10.1101/gr.163485.113. * Equal Last Authors
Skulte KA, Phan L, Clark SJ* and Taberlay PC* (2014). Chromatin remodeler mutations in human cancers: epigenetic implications. Epigenomics 6:397-414. * Equal Last Authors (Review)
Robinson MD, Strbenac D, Stirzaker C, Statham AL, Song J, Speed TP and Clark SJ (2013). Copy-number-aware differential analysis of DNA sequencing data.
Genome Research 22:2489-2496.
Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, Sutherland RL, Coolen MW, Stirzaker C and Clark SJ (2013). Regional activation of the cancer genome by long range epigenetic remodelling. Cancer Cell 23:9-22.
Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, Stirzaker C, Qu W, Nair S, Horvath LG, Armstrong NJ, Kench JG, Sutherland RL and Clark SJ (2013). Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene 32:2891-9.
Valdes-Mora F, Song JZ, Statham AL, Strbenac D, Robinson MD, Nair SS, Patterson KI, Tremethick DJ, Stirzaker C and Clark SJ (2012). Acetylation of H2A.Z is a key epigenetic modification associated with gene deregulation and epigenetic remodeling in cancer. Genome Res 22:307-321.
Statham AL, Robinson MD, Song JZ, Coolen MW, Stirzaker C and Clark SJ (2012). Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq)
directly informs methylation status of histone-modified DNA. Genome Res 22:1120-1127.
Locke WJ and Clark SJ (2012). Epigenome remodelling in breast cancer: insights from an early in vitro model of carcinogenesis. Breast Cancer Res
Gloss BS, Patterson KI, Barton CA, Gonzalez M, Scurry JP, Hacker NF, Sutherland RL, O'Brien PM and Clark SJ (2012). Integrative genome-wide expression and promoter DNA methylation profiling identifies a novel panel of ovarian cancer epigenetic biomarkers. Cancer Lett 318:76-85.
Wiklund ED, Gao S, Hulf T, Sibbritt T, Nair S, Costea DE, Villadsen SB, Bakholdt V, Bramsen JB, Sorensen JA, Krogdahl A, Clark SJ* and Kjems J* (2011). MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS One 2011; 6:e27840. *Equal Last Authors
Patterson K, Molloy L, Qu W and Clark SJ (2011). DNA methylation: bisulphite modification and analysis. JoVE 56:e3170.
Nair SS, Coolen MW, Stirzaker C, Song JZ, Statham AL, Strbenac D, Robinson MD and Clark SJ (2011). Comparison of methyl-DNA immunoprecipitation (MeDIP)
and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias. Epigenetics
Lee HJ, Hinshelwood RA, Bouras T, Gallego-Ortega D, Valdes-Mora F, Blazek K, Visvader JE, Clark SJ* and Ormandy CJ* (2011). Lineage specific methylation of the Elf5 promoter in mammary epithelial cells. Stem Cells 29:1611-1619. * Equal Last Authors
Hulf T, Sibbritt T, Wiklund ED, Bert S, Strbenac D, Statham AL, Robinson MD and Clark SJ (2011). Discovery pipeline for epigenetically deregulated miRNAs in cancer: integration of primary miRNA transcription. BMC Genomics 12:54.
Hansen TB, Wiklund ED, Bramsen JB, Villadsen SB, Statham AL, Clark SJ and Kjems J (2011). miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA. EMBO J 2011; 30:4414-4422.
Devaney J, Stirzaker C, Qu W, Song JZ, Statham AL, Patterson KI, Horvath LG, Tabor B, Coolen MW, Hulf T, Kench JG, Henshall SM, Benito RP, Haynes A-M, Mayor R, Peinado MA, Sutherland RL and Clark SJ (2011). Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. Cancer Epidemiol Biomarkers Prev 20:148-159.
Wiklund ED, Kjems J and Clark SJ (2010). Epigenetic architecture and miRNA: reciprocal regulators. Epigenomics 2:823-840 (Review).
Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, Peter ME, Ørntoft TF, Kjems J* and Clark SJ* (2010). Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer128:1327-1334. * Equal Last Authors
Statham AL, Strbenac D, Coolen MW, Stirzaker C, Clark SJ and Robinson MD (2010). Repitools: an R package for the analysis of enrichment-based epigenomic data. Bioinformatics 26:1662-1663.
Robinson MD, Stirzaker C, Statham AL, Coolen MW, Song JZ, Nair SS, Strbenac D, Speed TP and Clark SJ (2010). Evaluation of affinity-based genome-wide DNA
methylation data: effects of CpG density, amplification bias, and copy number variation. Genome Research 20:1719-1729.
Robinson MD, Statham AL, Speed TP and Clark SJ (2010). Protocol matters: which methylome are you actually studying? Epigenomics 2:587-598 (Review).
Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, Moreno CS, Young AN, Varma V, Speed TP, Cowley M, Lacaze P, Kaplan W, Robinson MD and Clark SJ (2010). Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nature Cell Biology 12:235-246.
Hinshelwood RA, Melki JR, Huschtscha LI, Paul C, Song JZ, Stirzaker C, Reddel RR and Clark SJ (2009). Aberrant de novo methylation of the p16(INK4A) CpG
island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning. Hum Mol Genet 18:3098-3109.
Hinshelwood RA, Huschtscha LI, Melki J, Stirzaker C, Abdipranoto A, Vissel B, Ravasi T, Wells CA, Hume DA, Reddel RR and Clark SJ (2007). Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis. Cancer Research 67:11517-11527.
Coolen MW, Statham AL, Gardiner-Garden M and Clark SJ (2007). Genomic profiling of CpG methylation and allelic specificity using quantitative high- throughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res 35:e119.
Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA and Clark SJ (2006). Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nature Genetics 38:540-549.
Clark SJ, Statham A, Stirzaker C, Molloy PL and Frommer M (2006). DNA methylation: Bisulphite modification and analysis. Nature Protocols 1:2353-2364.
Prior to 2006
Stirzaker C, Song JZ, Davidson B and Clark SJ (2004). Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res, 64:3871-3877.
Song JZ, Stirzaker C, Harrison J, Melki JR and Clark SJ (2002). Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene, 21:1048-1061.
Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, Frommer M and Clark SJ (1997). Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res, 57:2229-2237.
Clark SJ, Harrison J and Frommer M (1995). CpNpG methylation in mammalian-cells. Nat Genet, 10:20-27.